ACADIA Pharmaceuticals Stock Forecast
NASDAQ: ACADHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 19.58 0.00%
ACAD analyst consensus
Consensus (20 analysts)
buy
Avg. price target
$32.16+64.25%
- Strong buy 4
- Buy 11
- Hold 4
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 20 Wall Street analysts covering ACADIA Pharmaceuticals (2026-10-07), 15 rate the stock a buy or strong buy, 4 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $32.16, with a high estimate of $49.00 and a low estimate of $17.00. The average target implies upside of 64.2% from the current price of $19.58.
The spread between the highest and lowest targets is 188.2%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ACAD.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 4 | 20% |
| Buy | 11 | 55% |
| Hold | 4 | 20% |
| Sell | 1 | 5% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $17.00 | -13.18% |
| Average target | $32.16 | +64.25% |
| High target | $49.00 | +150.26% |